Long-Term Observation of the Safety and Effectiveness of Enzyme Replacement Therapy in Japanese Patients with Pompe Disease: Results From the Post-marketing Surveillance
Abstract Introduction Alglucosidase alfa received marketing approval for the treatment of Pompe disease in Japan in 2007. We conducted a post-marketing surveillance study to monitor the long-term safety and efficacy of alglucosidase alfa therapy among Japanese patients with Pompe disease. Methods Th...
Main Authors: | Hitoshi Nagura, Jiro Hokugo, Kazuo Ueda |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2019-09-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1007/s40120-019-00157-4 |
Similar Items
-
Benefit of 5 years of enzyme replacement therapy in advanced late onset Pompe. A case report of misdiagnosis for three decades with acute respiratory failure at presentation
by: Mandat Maharaj, et al.
Published: (2022-09-01) -
Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy
by: Hui-An Chen, et al.
Published: (2024-04-01) -
Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry
by: Priya S. Kishnani, et al.
Published: (2023-12-01) -
Efficacy and safety of enzyme replacement therapy with alglucosidase alfa for the treatment of patients with infantile-onset Pompe disease: a systematic review and metanalysis
by: A. D. Dornelles, et al.
Published: (2024-02-01) -
Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
by: Imke A. M. Ditters, et al.
Published: (2023-05-01)